| Literature DB >> 35666066 |
Joanna Sophia J Vinke1, Hanneke J C M Wouters2,3, Suzanne P Stam1, Rianne M Douwes1, Adrian Post1, Antonio W Gomes-Neto1, Melanie M van der Klauw3, Stefan P Berger1, Stephan J L Bakker1, Martin H De Borst1, Michele F Eisenga1.
Abstract
BACKGROUND: Post-transplant anaemia and reduced muscle mass and strength are highly prevalent in kidney transplant recipients (KTRs). Decreased haemoglobin levels, a marker of anaemia, could adversely affect muscle mass and strength through multiple mechanisms, among others, through diminished tissue oxygenation. We aimed to investigate the association between haemoglobin levels with muscle mass and strength in KTRs.Entities:
Keywords: 24 h urinary creatinine excretion; Haemoglobin levels; Handgrip strength; Kidney transplant recipients
Mesh:
Substances:
Year: 2022 PMID: 35666066 PMCID: PMC9397498 DOI: 10.1002/jcsm.12999
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.063
Baseline characteristics of 871 kidney transplant recipients
| All | Age‐specific and sex‐specific quartiles of haemoglobin levels |
| ||||
|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | |||
| Number of participants (%) | 871 | 208 (24) | 217 (25) | 213 (24) | 233 (27) | |
| Demographics | ||||||
| Age, years | 58 (48–66) | 57 (46–66) | 57 (47–65) | 61 (48–68) | 57 (49–65) | 0.03 |
| Men, | 520 (60) | 128 (62) | 127 (59) | 129 (61) | 136 (58) | 0.88 |
| Body mass index, kg/m2 | 27.3 ± 4.8 | 26.9 ± 5.1 | 27.2 ± 4.9 | 28.0 ± 4.8 | 27.3 ± 4.4 | 0.13 |
| Laboratory parameters | ||||||
| Haemoglobin, g/dL | ||||||
| Men | 13.9 ± 1.8 | 11.6 ± 0.9 | 13.3 ± 0.5 | 14.4 ± 0.4 | 16.0 ± 0.9 | <0.001 |
| Women | 12.8 ± 1.5 | 10.7 ± 0.8 | 12.3 ± 0.3 | 13.2 ± 0.2 | 14.5 ± 0.8 | <0.001 |
| MCV, fL | 89.3 ± 5.9 | 89.0 ± 7.3 | 89.7 ± 5.8 | 89.4 ± 5.1 | 89.0 ± 5.1 | 0.52 |
| Ferritin, μg/L | 91 (41–187) | 105 (35–219) | 99 (37–169) | 85 (40–200) | 87 (49–168) | 0.92 |
| Iron, μmol/L | 13.9 ± 5.4 | 11.6 ± 5.3 | 13.5 ± 4.8 | 14.6 ± 5.4 | 15.3 ± 5.3 | <0.001 |
| Transferrin, g/L | 2.41 ± 0.43 | 2.34 ± 0.52 | 2.41 ± 0.44 | 2.43 ± 0.38 | 2.45 ± 0.38 | 0.08 |
| Transferrin saturation, % | 23.8 ± 10.1 | 21.1 ± 10.6 | 23.1 ± 9.3 | 24.6 ± 9.9 | 25.8 ± 10.1 | <0.001 |
| eGFR, mL/min/1.73 m2 | 51 ± 18 | 42 ± 17 | 51 ± 17 | 54 ± 18 | 57 ± 15 | <0.001 |
| hs‐CRP, mg/L | 1.9 (0.8–4.6) | 2.4 (0.9–6.0) | 1.8 (0.7–4.4) | 1.6 (0.8–4.1) | 1.8 (0.7–3.8) | 0.03 |
| Urinary creatinine excretion, mmol/24 h | 12.4 ± 3.8 | 11.9 ± 3.8 | 12.5 ± 3.9 | 12.3 ± 3.7 | 12.7 ± 3.7 | 0.16 |
| Urinary protein excretion, g/24 h | 0.17 (0.12–0.30) | 0.20 (0.12–0.54) | 0.17 (0.13–0.26) | 0.16 (0.12–0.28) | 0.15 (0.11–0.25) | 0.002 |
| Urinary urea excretion, mmol/24 h | 381 ± 119 | 357 ± 102 | 387 ± 124 | 389 ± 122 | 389 ± 122 | 0.01 |
| Lifestyle parameters | ||||||
| Alcohol intake, units/week | 0.12 | |||||
| None, | 350 (45) | 92 (50) | 89 (45) | 83 (45) | 86 (40) | |
| 0–7 units per week, | 265 (34) | 60 (32) | 67 (34) | 70 (38) | 68 (32) | |
| >7 units per week, | 166 (21) | 34 (18) | 40 (20) | 32 (17) | 60 (28) | |
| Smoking, | 84 (11) | 14 (8) | 22 (12) | 22 (13) | 26 (13) | 0.32 |
| CIS fatigue score | 61 (42–82) | 65 (43–84) | 60 (41–84) | 62 (42–83) | 58 (42–78) | 0.34 |
| Transplant parameters | ||||||
| Time since transplantation, years | 3.5 (1.0–10.2) | 5.0 (1.0–11.6) | 2.0 (1.0–8.6) | 3.1 (1.0–8.0) | 4.0 (1.0–11.9) | 0.06 |
| Type of donor | 0.55 | |||||
| Living, | 481 (55) | 113 (55) | 129 (59) | 113 (53) | 126 (54) | |
| Postmortal, | 389 (45) | 94 (45) | 88 (41) | 100 (47) | 107 (46) | |
| Medication use | ||||||
| Calcineurin inhibitor, | 722 (83) | 182 (88) | 189 (87) | 177 (83) | 174 (75) | 0.001 |
| Antiproliferative agent, | 746 (86) | 169 (81) | 185 (85) | 184 (86) | 208 (89) | 0.12 |
| Prednisone, | 849 (98) | 204 (98) | 211 (97) | 207 (97) | 227 (97) | 0.93 |
| Oral iron supplements, | 65 (8) | 36 (17) | 15 (7) | 10 (5) | 4 (2) | <0.001 |
| Statin, | 497 (57) | 120 (58) | 116 (54) | 126 (59) | 135 (58) | 0.65 |
| RAAS inhibitor, | 335 (39) | 96 (46) | 91 (42) | 73 (34) | 75 (32) | 0.01 |
| Handgrip strength, kg | 34 ± 12 | 33 ± 12 | 34 ± 11 | 34 ± 11 | 35 ± 13 | 0.21 |
| Appendicular skeletal muscle mass, kg | 22.9 ± 5.6 | 22.6 ± 5.0 | 23.1 ± 6.3 | 23.5 ± 6.3 | 22.4 ± 4.8 | 0.22 |
| Five times sit to stand test, s | 12.1 ± 3.6 | 12.9 ± 3.9 | 12.0 ± 3.3 | 12.4 ± 4.5 | 11.5 ± 2.8 | 0.08 |
eGFR, estimated glomerular filtration rate; MCV, mean corpuscular volume; Hs‐CRP, high sensitive C‐reactive protein; RAAS, renin‐angiotensin‐aldosterone system.
Data are presented as mean ± standard deviation (SD), median with interquartile range (IQR), or number (n) with percentage (%). Data on alcohol intake were available for 781 KTRs. Data on subjective fatigue were available for 764 KTRs. Data on smoking status were available for 751 KTRs. Appendicular skeletal muscle mass was measured in 814 KTRs. Handgrip strength was determined in 854 KTRs. The five times sit to stand test was performed in 290 KTRs.
Linear regression of the association between haemoglobin levels with different measurements of muscle mass and strength
| Creatinine excretion rate (mmol/24 h) | Appendicular skeletal muscle mass (kg) | Handgrip strength (kg) | Five times sit to stand test score (s) | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
| Std. β |
| Std. β |
| Std. β |
| Std. β |
| |
| Haemoglobin | ||||||||
| Univariable | 0.24 | <0.001 | 0.20 | <0.001 | 0.31 | <0.001 | −0.15 | 0.01 |
| Multivariable | 0.07 | 0.01 | 0.22 | <0.001 | 0.15 | <0.001 | −0.17 | 0.02 |
BMI, body mass index; eGFR, estimated glomerular filtration rate; hs‐CRP, high sensitive C‐reactive protein; RAAS, renin‐angiotensin‐aldosterone system.
Model 1: Crude analysis (univariable model) Model 2: Multivariable model, adjusted for age, sex, eGFR, BMI, natural log of hs‐CRP, serum iron, natural log of urinary protein excretion, urinary urea excretion, natural log of transplantation vintage, type of donor, subjective fatigue score, smoking status, alcohol intake and use of calcineurin inhibitors, antiproliferative agents, systemic corticosteroids, statins, oral iron supplements, and RAAS‐inhibitors. For fatigue score, smoking status, and alcohol intake, imputed data were used.
In case of appendicular skeletal muscle mass, age, sex, and BMI were not included in Model 2 because these variables are included in the formula of Kyle.
A higher score reflects worse performance.
Figure 1Haemoglobin levels and measurements of muscle mass and strength. The correlation and Spearman's rank correlation coefficient between haemoglobin levels and creatinine excretion rate (CER) (A), appendicular skeletal muscle mass (ASMM) (B), handgrip strength (C), and five times sit to stand test score (FTSTS) (D). The grey area represents the 95% confidence interval of the regression line. Data on CER available in 871 KTRs, data on ASMM available in 814 KTRs, data on handgrip strength available in 854 KTRs, and data on FTSTS available in 290 KTRs.
Age‐specific and sex‐specific quartiles of haemoglobin levels and the risk of being in the worst age‐specific and sex‐specific quartile of different measures of muscle mass and strength
| Lowest quartile of creatinine excretion rate (mmol/24 h) | Lowest quartile of appendicular skeletal muscle mass (kg) | Lowest quartile of handgrip strength (kg) | Highest quartile of five times sit to stand test score (s) | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
| Age‐specific and sex‐specific quartile of haemoglobin level | ||||||||
| Univariable | ||||||||
| Quartile 1 | 2.10 (1.35–3.26) | 0.001 | 0.92 (0.58–1.45) | 0.72 | 2.00 (1.31–3.07) | 0.001 | 5.07 (2.19–11.77) | <0.001 |
| Quartile 2 | 1.54 (0.98–2.41) | 0.06 | 1.05 (0.68–1.62) | 0.84 | 1.17 (0.75–1.83) | 0.49 | 3.09 (1.30–7.34) | 0.01 |
| Quartile 3 | 1.05 (0.66–1.69) | 0.83 | 0.94 (0.60–1.47) | 0.79 | 1.22 (0.78–1.90) | 0.39 | 2.54 (1.01–6.40) | 0.05 |
| Quartile 4 | Reference | Reference | Reference | Reference | ||||
| Multivariable | ||||||||
| Quartile 1 | 2.09 (1.15–3.77) | 0.02 | 1.38 (0.80–2.37) | 0.25 | 3.30 (1.95–5.59) | <0.001 | 7.21 (2.59–20.05) | <0.001 |
| Quartile 2 | 1.94 (1.12–3.39) | 0.02 | 1.55 (0.95–2.52) | 0.08 | 1.51 (0.92–2.48) | 0.11 | 3.12 (1.20–8.08) | 0.02 |
| Quartile 3 | 1.12 (0.63–1.99) | 0.70 | 1.04 (0.64–1.67) | 0.89 | 1.27 (0.78–2.06) | 0.34 | 2.33 (0.86–6.30) | 0.10 |
| Quartile 4 | Reference | Reference | Reference | Reference | ||||
BMI, body mass index; eGFR, estimated glomerular filtration rate; hs‐CRP, high sensitive C‐reactive protein; RAAS, renin‐angiotensin‐aldosterone system.
Odds ratios and corresponding 95% confidence intervals are presented for the being in the lowest age‐specific and sex‐specific quartile of CER, appendicular skeletal muscle mass or handgrip strength or in the highest age‐specific and sex‐specific quartile of FTSTS test score. Model 1: Crude analysis (univariable model). Model 2**: Multivariable model, adjusted for eGFR, BMI, natural log of hs‐CRP, serum iron, natural log of urinary protein excretion, urinary urea excretion, natural log of transplantation vintage, type of donor, subjective fatigue score, smoking status, alcohol intake and use of calcineurin inhibitors, antiproliferative agents, systemic corticosteroids, statins, oral iron supplements, and RAAS inhibitors. For fatigue score, smoking status, and alcohol intake, imputed data were used.
In case of appendicular skeletal muscle mass, age, sex and BMI were not included in Model 2 because these variables are included in the formula of Kyle.
A higher score reflects worse performance.